Abstract
Blood products are a valuable resource, derived from altruistic donations. They undergo high-cost screening and modification to decrease the risk of transfusion-transmitted infection. Although blood products have achieved a high level of safety, significant risks associated with transfusion remain. To avoid unnecessary transfusions, patient blood management involves optimising red cell mass, minimising blood loss, and optimising physiological tolerance of anaemia. A circumspect approach to prescribing blood products is recommended. Regular patient assessment in conjunction with judicious laboratory testing are the primary considerations in the decision to transfuse. Evidence-based guidelines for the appropriate use of blood products have been released by the National Blood Authority.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
